CicloMed LLC is a developmental-stage pharmaceutical company that aims to improve the lives of cancer patients, specifically those suffering from bladder cancer. Bladder cancer is a major health concern, causing nearly 200,000 deaths worldwide each year and burdening survivors with ongoing medical procedures and treatments. CicloMed is dedicated to changing this narrative by developing a groundbreaking drug candidate called Fosciclopirox (Ciclopirox Prodrug).

Fosciclopirox is a novel agent specifically targeting bladder cancer, and it is being evaluated in Phase I clinical studies. The initial first-in-human study in 2019 confirmed the compound's safety, dose tolerance, pharmacokinetics, and pharmacodynamics in advanced cancer patients. CicloMed is now conducting a Phase I expansion cohort study to evaluate Fosciclopirox in patients with muscle-invasive bladder cancer.

This innovative drug has the potential to transform bladder cancer treatment by improving patient outcomes and reducing recurrences. CicloMed's approach to bladder cancer is the result of a successful public-private partnership with The University of Kansas Cancer Center, where scientists discovered Ciclopirox Prodrug's anticancer abilities in preclinical models. The licensing of Ciclopirox Prodrug to CicloMed in 2015 marked the beginning of this collaborative effort.

CicloMed is also involved in an open-label, Phase 1B/2A study to investigate the efficacy and safety of Fosciclopirox in combination with cytarabine for patients with relapsed or refractory acute myeloid leukemia (AML). As a portfolio company of BioNovus Innovations LLC, CicloMed benefits from a strong financial investment and commitment to bringing novel healthcare solutions to reality